Compare BridgeBio Pharma Inc (BBIO) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Peloton Interactive Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Peloton Interactive Inc trades at $5.6 (market cap $2.42B). The key difference: BridgeBio Pharma Inc is far larger — about 6.9× Peloton Interactive Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | PTON | |
|---|---|---|
Market Cap | $16.61B | $2.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $9.00 |
52-Week Low | $47.29 | $3.71 |
Enterprise Value | $18.16B | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Peloton Interactive (PTON) trades at $5.68, up 3.18% with a bearish technical signal despite recent earnings beat. The company achieved its first annual net profit in fiscal 2026 with $63M net income, though revenue declined to $2.4B. Valuation metrics show a P/E of 40.54 and P/S of 1.01, while negative shareholder equity of -$413.7M reflects historical losses. Recent news highlights profitability progress but concerns about subscriber declines and conservative 2027 guidance.
PTON presents a turnaround story with improving profitability but faces significant revenue headwinds. The stock offers potential upside if subscriber stabilization occurs, though high debt levels and competitive pressures pose substantial risks. Analyst consensus is divided with 50% buy ratings, suggesting cautious optimism amid ongoing business transformation challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
